Alliance A031902 (CASPAR): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
- Citation:
- J Clin Oncol vol 40 (suppl 6) TPS194
- Meeting Instance:
- ASCO GU 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- Yes
- Parents:
- None
- Children:
- None
- Pharmas:
- Clovis Oncology
- Grants:
- U10CA180821, U10CA180882, U24CA196171; U10CA180820 (ECOG-ACRN); U10CA180868 (NRG); U10CA180888 (SWOG);
- Corr. Author:
- Authors:
- Arpit Rao Glenn Heller Charles J. Ryan David James VanderWeele Lionel D Lewis Alan Tan Colleen Watt Ronald C. Chen Manish Kohli Pedro Barata Benjamin Gartrell Robert Grubb Amylou Dueck Yujia Wen Michael J. Morris
- Networks:
- KANSAS, LAPS-IL036, LAPS-MN026, LAPS-NH012, LAPS-NY016, LAPS-UT003, MN022, MONTEFIORE, MUSC, TX041
- Study
- Alliance-A031902
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: